Transcription profiling of human AML cell line OCI/AML2 treated with valproic acis and all trans retinoic acid

ABSTRACT: Purpose: Treatment of acute promyelocytic leukemia (APL) with the retinoid, all trans retinoic acid (ATRA), along with standard chemotherapy has significantly improved survival compared to chemotherapy alone1. ATRA mediates its benefit in APL by overcoming the transcriptional block mediated by PML-RAR fusion oncoprotein, thereby, restoring expression of retinoid response genes2. The therapeutic benefits observed with ATRA treatment in APL have not been achieved in the other more common sub-types of acute myeloblastic leukemia (AML)3. This likely reflects the recruitment of histone deacetylase complexes by other recurrent chromosomal translocations in AML cells4. In this experiment, we evaluated if treatment of the AML cell line, OCI/AML-2, with the histone deacetylase inhibitor, valproi

ORGANISM(S): Homo sapiens

SUBMITTER: Mark Minden 

PROVIDER: E-GEOD-2668 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress